Four ways Academic Medical Centers can capture greater value in the Cell & Gene Therapy industry

Read the full Cell & Gene article

Academic medical centers (AMCs) are unique in the way academic functions and healthcare delivery services are co-located. With strong research capabilities, access to leading scientists, clinicians, and experts in other disciplines such as bioengineers and ethicists, healthcare delivery infrastructures, and access to patients, AMCs are uniquely positioned to conduct cutting-edge research and test the efficacy of novel medicines.

Over the past 15 years, academic medical centers have played a key role in the discovery of novel therapies for unmet medical demands such as cell and gene therapies (CGTs). The first autologous CAR-T therapy, for example, was developed by researchers at the University of Pennsylvania (UPenn) and administered at the Children's Hospital of Philadelphia.

CGTs provide a novel and truly transformative solution to a number of health conditions and unmet clinical needs such as blood cancers, neurodegenerative diseases, and rare genetic disorders. While they have not yet delivered their full potential and are not yet widely adopted in clinical practice across the globe, CGTs are already changing the way we will approach drug development and disease treatment in the future.